Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Both approaches may offer a nonpharmaceutical option to use instead of or alongside opioids pain medication.
Tumor-treating fields therapy uses electricity delivered via a wearable device to kill cancer cells.
Osimertinib led to a 51% improvement in survival, but some say the placebo group did not receive adequate treatment.
A study led by researchers at the American Cancer Society looked at 51,000 women ages 18 to 39 who had been diagnosed with breast cancer.
Responders may be able to discontinue immune checkpoint inhibitors after two years with no decrease in survival.
Food insecurity and worry about paying for housing and other necessities were associated with higher mortality.
The targeted therapy delayed disease progression in patients with the most common type of early-stage breast cancer.
A one percentage point increase in the population with medical debt was associated with an increase in mortality for all malignancies.
The daily medication led to improvements in libido, sexual function and overall quality of life.
Moderna and Merck’s customized neoantigen vaccine plus Keytruda lowered the risk for metastasis or death by 65%.
Black cancer survivors also have a higher risk of death from heart disease, new study shows.
Women who agreed to more screenings had a significantly lower risk of death.
Jail incarceration was associated with increased cancer deaths for common cancers for white people, but not for Black people.
The oral targeted therapy led to a 51% improvement in survival for patients with EGFR-mutated non-small-cell lung cancer.
Vorasidenib prolonged progression free survival and delayed radiation and chemotherapy for IDH-mutant glioma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.